KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Vir Biotechnology (VIR) over the last 6 years, with Q3 2025 value amounting to -$11000.0.

  • Vir Biotechnology's Other Operating Expenses fell 10008.62% to -$11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 10769.7%. This contributed to the annual value of $35.8 million for FY2024, which is 11955.4% up from last year.
  • As of Q3 2025, Vir Biotechnology's Other Operating Expenses stood at -$11000.0, which was down 10008.62% from -$161000.0 recorded in Q2 2025.
  • Vir Biotechnology's Other Operating Expenses' 5-year high stood at $90.1 million during Q1 2022, with a 5-year trough of -$3.3 million in Q4 2024.
  • Moreover, its 5-year median value for Other Operating Expenses was $5.5 million (2023), whereas its average is $14.7 million.
  • As far as peak fluctuations go, Vir Biotechnology's Other Operating Expenses surged by 234064.69% in 2022, and later tumbled by 19090.91% in 2025.
  • Quarter analysis of 5 years shows Vir Biotechnology's Other Operating Expenses stood at $56.9 million in 2021, then tumbled by 89.46% to $6.0 million in 2022, then fell by 6.29% to $5.6 million in 2023, then tumbled by 158.02% to -$3.3 million in 2024, then skyrocketed by 99.66% to -$11000.0 in 2025.
  • Its Other Operating Expenses was -$11000.0 in Q3 2025, compared to -$161000.0 in Q2 2025 and -$10000.0 in Q1 2025.